Patents by Inventor Jérôme Frenette

Jérôme Frenette has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF RANK/RANKL ANTAGONISTS FOR TREATING NEUROMUSCULAR DISORDERS, GENETIC MYOPATHIES AND/OR NON GENETIC MYOPATHIES AND/OR FOR REGULATING SKELETAL AND CARDIAC MUSCLE DISUSE, DISEASES AND AGING
    Publication number: 20180064810
    Abstract: The present invention relates to uses and methods comprising one or more RANK/RANKL antagonists or of a pharmaceutical composition comprising one or more RANK/RANKL antagonists and a pharmaceutically acceptable carrier for treating neuromuscular disorders, non-genetic myopathies, or genetic myopathies; maintaining and/or preserving the excitation:contraction:relaxation coupling; reducing loss of muscle strength associated with neuromuscular disorders, non-genetic myopathies or genetic myopathies; reducing the loss of muscular strength associated with skeletal or cardiac muscle disuse, diseases and aging; or regulating skeletal or cardiac muscle disuse, diseases and/or aging in a patient in need thereof. The present invention also relates to combinations and compositions comprising one or more RANK/RANKL antagonists and to methods for identifying candidate compounds.
    Type: Application
    Filed: September 11, 2017
    Publication date: March 8, 2018
    Inventors: Jérôme FRENETTE, Josef PENNINGER
  • Use of RANK/RANKL antagonists for treating muscular dystrophy
    Patent number: 9757451
    Abstract: The present invention relates to uses and methods comprising one or more RANK/RANKL antagonists or of a pharmaceutical composition comprising one or more RANK/RANKL antagonists and a pharmaceutically acceptable carrier for treating neuromuscular disorders, non-genetic myopathies, or genetic myopathies; maintaining and/or preserving the excitation:contraction:relaxation coupling; reducing loss of muscle strength associated with neuromuscular disorders, non-genetic myopathies or genetic myopathies; reducing the loss of muscular strength associated with skeletal or cardiac muscle disuse, diseases and aging; or regulating skeletal or cardiac muscle disuse, diseases and/or aging in a patient in need thereof. The present invention also relates to combinations and compositions comprising one or more RANK/RANKL antagonists and to methods for identifying candidate compounds.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: September 12, 2017
    Assignee: UNIVERSITÉ LAVAL
    Inventors: Jérôme Frenette, Josef Penninger
  • USE OF RANK/RANKL ANTAGONISTS FOR TREATING NEUROMUSCULAR DISORDERS, GENETIC MYOPATHIES AND/OR NON GENETIC MYOPATHIES AND/OR FOR REGULATING SKELETAL AND CARDIAC MUSCLE DISUSE, DISEASES AND AGING
    Publication number: 20140302023
    Abstract: A pharmaceutical composition includes one or more RANK/RANKL antagonists and a pharmaceutically acceptable carrier. The composition can be used for treating neuromuscular disorders, non-genetic myopathies, or genetic myopathies; maintaining and/or preserving the excitation:contraction:relaxation coupling; reducing loss of muscle strength associated with neuromuscular disorders, non-genetic myopathies or genetic myopathies; reducing the loss of muscular strength associated with skeletal or cardiac muscle disuse, diseases and aging; or regulating skeletal or cardiac muscle disuse, diseases and/or aging in a patient in need thereof. Methods are used to identify candidate compounds.
    Type: Application
    Filed: November 6, 2012
    Publication date: October 9, 2014
    Inventors: Jérôme Frenette, Josef Penninger